Interpretation, context, and actionability: Navigating low-level ctDNA positives

Signatera™ to evaluate molecular response to investigational dendritic cell therapy as part of Diakonos’ Phase I/II trial AUSTIN, Texas–(BUSINESS WIRE)– Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As […]

Signatera™ will be used to identify patients who may be able to delay or defer adjuvant CDK4/6 inhibitor therapy in intermediate-risk HR+/HER2- breast cancer SIGNAL is a new group of Natera-sponsored interventional trials designed to establish the clinical utility of MRD-guided treatment de-escalation strategies across multiple cancer types AUSTIN, Texas–(BUSINESS WIRE)– Natera, Inc. (NASDAQ: NTRA), […]

Marks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions Solidifies Natera’s Treatment on MRD (TOMR) approach as the new standard of care ...

New data. Better insight. The future of precision breast cancer care.

Signatera™ MRD testing for HNSCC patient management

From ASCO GU to Real-World Practice: ctDNA in Bladder Cancer Management

Shaping the future of skin cancer: Tumor-informed ctDNA-guided interventions

STELLAR-316 will use Natera’s Signatera™ assay to identify MRD-positive patients for trial enrollment and to monitor response to therapy  ALAMEDA, Calif. and AUSTIN, Texas– Exelixis, Inc. (Nasdaq: EXE...